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Ribosome biogenesisBowen–Conradi syndrome (BCS) is a ribosomopathy characterized by severe developmental delay and growth
failure that typically leads to death by one year of age. It is caused by a c.257ANG, p.D86G substitution in the ri-
bosomal biogenesis protein, Essential for Mitotic Growth 1 (EMG1). We generated a knock-in of the D86G sub-
stitution in mice to characterize the effects of EMG1 deﬁciency, particularly in the brain, where EMG1
expression is high. Embryos homozygous for the mutation in Emg1 were small for gestational age with neural
tube defects, and died between embryonic days 8.5 and 12.5. These embryos exhibited dramatically reduced
cell proliferation, which we also detected in autopsy brain tissue and bone marrow of BCS patients, consistent
with a requirement for high levels of EMG1 in tissues with rapid cell proliferation. In ﬁbroblasts derived from
the BCS mouse embryos, we detected a high proportion of binucleated cells, indicating that a mitotic defect un-
derlies the growth arrest in BCS. These studies add to growing evidence of a link between ribosome biogenesis,
mitotic progression, and brain development that is currently unexplored.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Bowen–Conradi syndrome (BCS; OMIM#211180) is a lethal autoso-
mal recessive disorder exclusive to the Hutterite population, and be-
longing to the ribosomopathies, a group of diseases caused by defects
in ribosomebiogenesis. BCS is currently the only ribosomopathy charac-
terized by severe neurological impairment from birth, and is accompa-
nied by severe pre- and post-natal growth delay and failure to thrive,
leading to death at an average age of thirteen months [1]. It is caused
by a c.257ANG, p.D86G (reference sequence GenBank # NM_006331., Essential forMitotic Growth 1;
rdU,bromodeoxyuridine;E, em-
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).7) mutation in the gene Essential for Mitotic Growth 1 (EMG1) [2],
encoding a methyltransferase shown to modify the nascent 18S rRNA
in yeast; in BCS patient cell lines, mutation in EMG1 results in a delay
in 18S rRNA processing and reduces proliferation [3,4]. Autopsies on in-
fants who have died from BCS are rare, and the majority of investiga-
tions have been performed on patient cells obtained from peripheral
blood or skin biopsies [2,4,5]. Therefore, to study the effect of the
EMG1mutation on multiple tissues in organism development and sur-
vival, an animal model is necessary. Human and mouse EMG1 proteins
are 89% identical, complement a yeast deﬁciency [6,7], and likely share a
similar function to yeast Emg1. In addition, the D86 residue mutated in
BCS is conserved in mouse EMG1 [2], making mouse a viable organism
in which to model the BCS phenotype.
We previously generated an Emg1 null (Emg1−/−) mouse by replac-
ing exons 2–6 with a SA-IRES-βgeo cassette [8]. Heterozygotes ap-
peared normal, while a complete deﬁciency was pre-implantation
lethal with growth arrested between embryonic day (E) 2.5 and E3.5.
This growth arrest was accompanied by increased cell death, reduced
proliferation, and early lethality that precluded the examination of
tissues or generation of cell lines deﬁcient in EMG1. Ablation of the
TRP53 checkpoint can rescue the phenotype in mouse models of some
Fig. 1. EMG1 expression in mouse brain throughout development and in adulthood. Strong,
even EMG1expressionwas observed in the neuroepitheliumat E7.5 (arrow) (A), in themid-
and hindbrain and the choroid plexus (arrowhead) at E12.5 (B), and began to becomemore
restricted by E16.5 (C), when strongest expression in the cortexwas found in the superﬁcial
layer of the cortical plate (arrow). Postnatally, the most concentrated areas of expression
were the dentate gyrus of the hippocampus at postnatal days seven (D) and six weeks (F),
and the Purkinje neurons (arrowhead) and granular layer neurons of the cerebellum at six
weeks (G). EMG1 was also found in oligodendrocytes in postnatal day 14 mice (E, arrow-
head). Scale bar= 500 μm at 5× and 100 μmat 20×. am, amnion; ch, chorion; chp, choroid
plexus; cp, cortical plate; dg, dentate gyrus; fb, forebrain; gl, granular layer; hb, hindbrain;
mb; midbrain; ml, molecular layer; ne, neuroepithelium; op, oropharynx; pc, Purkinje cell;
tg, trigeminal ganglion; vent, ventricle; vz, ventricular zone.
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and 5q- syndrome [10], as well asmutations in ribosomal protein genes
Rps20 [11], Rpl24 [12], and Rps7 [13]. In contrast, TRP53 deﬁciency failed
to rescue the Emg1−/− phenotype, suggesting that the defect in these
mice is not mediated by the TRP53 pathway.
To produce a model more similar to that of BCS patients, we gener-
ated a mouse with a knock-in of themutation causing the D86G substi-
tution. The homozygous mutant (Emg1G/G) mice were severely
developmentally delayed, and died between E8.5 and E12.5. Growth re-
tardation was accompanied by an incompletely penetrant neural tube
defect, decreased cell proliferation, and increased apoptosis. Ki67 stain-
ing in BCS patient tissues, including the brain, conﬁrmed a similar cell
proliferation defect. Cell lines derived from the Emg1G/G embryos fre-
quently displayed two nuclei, indicating a mitotic progression defect
which likely accounts for the cell proliferation delay. These results
establish this Emg1G/G mouse as a model to study many features of
BCS and other ribosomopathies. Further, in the context of other studies,
our ﬁndings indicate that a link between ribosome biogenesis and mi-
totic progression should be explored.
2. Materials and methods
2.1. Cell culture
Mouse embryonic stem (ES) cell cultures were grown according
to established methods [14]. Mouse embryonic ﬁbroblasts (MEFs)
were cultured in Dulbecco's modiﬁed Eagle's medium containing
10% FBS, 200 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin. Cells were maintained in a humidiﬁed chamber at
37 °C in 5% CO2.
2.2. Generation of EMG1 D86G mouse
The Emg1 targeting construct was cloned essentially as previously
described [15], using PCR-directed mutagenesis to insert an ANGmuta-
tion in exon 2. The targeting vectorwas sequenced and linearized before
electroporation into R1 ES cells derived from C129mice. From 192 col-
onies, two independent correctly targeted clones were selected to gen-
erate chimeras, following screening for the presence of the 5 arm, the 3
arm, and the βgeo cassette by Southern blot (location indicated in
Fig. S1), and for the 3 loxP site (767 5 -TGA CCT TTA GCA AGC ATG
GAG-3 and768 5 -CTA TCT TGGAAC TATACCAG-3 ) and theA to Gmu-
tation (808 5 -CAT GTT CTG TTC TGC AGG TAG-3 and 809 5 -GCT CTG
CCC ACA CAG ATA GCT-3 ) by PCR. Two independent correctly targeted
clones were chosen for aggregation with wild type morulae from CD1
mice, performed using standard protocols [14]. Blastocysts were im-
planted into pseudopregnant females, and male chimeras transmitting
the mutant allele to the germ line were crossed with wild type CD1 fe-
males. To remove the SAIRES-βgeo selection cassette, resulting hetero-
zygous males were crossed with C57BL/6 females expressing Flp
recombinase from the ROSA 26 locus (Gt(ROSA)26Sortm1(FLP1)Dym, Jack-
son Labs) [16]. Pups were screened by PCR and Southern blot for the re-
moval of the selection cassette (βgeo cassette 806 5 -ACT GGC ATG TTC
CTC AGC AT-3 and 807 5 -GGA CAG GGA TAA GTA TGA CAT C-3 ; single
Frt site 773 5 -ACT GGC ATG TTC CTC AGC AT-3 and 774 5 -AAG CTT
GCG GAA CCC TTA AT-3 ).
2.3. Phenotypic analysis of homozygous mutants
Timed heterozygous crosses were performed, and the morning a
vaginal plug was discovered was considered E0.5. Timed pregnant fe-
males were sacriﬁced by cervical dislocation. To label cells in S phase
of the cell cycle, pregnant mice were injected intraperitoneally with
50 mg/kg bromodeoxyuridine (BrdU; Roche) in PBS, and sacriﬁced 2 h
post-injection.
Fig. 2. BCS embryomorphology. (A–H) Mid-sagittal sections of formaldehyde-ﬁxed, parafﬁn-embedded embryos stainedwith hematoxylin and eosin. At each time point, BCS and control
embryos are littermates, and a heterozygous control is shownwherever possible. Ventral is to the left, and rostral is at the top. (A, B) E7.5 putative BCS embryo and control. (C,D) E8.5. Note
the similarities between the BCS embryo at E8.5 and the control embryo at E7.5. (E, F) E9.5. (G,H) E10.5. Note the openneural tube in the cranial region of theBCS embryo (arrow). Original
magniﬁcation 5×, scale bar=500 μm; 20×, scale bar=100 μm. (I) Dissectingmicroscope photograph of E11.5 littermates. The neural tube in the BCS embryo is closed in this instance. (J)
E12.5 littermates. The secondBCS embryo has exencephaly in themidbrain region (arrowhead). am, amnion; al, allantois; ba, branchial arch; ch, chorion; fb, forebrain; fo, forelimbbud; he,
heart; hb, hindbrain; mb, midbrain; me, mesenchyme; ne, neuroepithelium; nt, neural tube; ys, yolk sac.
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Embryos were ﬁxed from 1 h to overnight in 4% formaldehyde
(titrated from paraformaldehyde), processed, and embedded in paraf-
ﬁn. Sections (5 μm)were stainedwith hematoxylin and eosin according
to standard protocols. For immunohistochemical analysis, sectionswere
deparafﬁnized, rehydrated, and subjected to antigen retrieval in 10mM
sodium citrate buffer (pH 6.0) heated to 95 °C. For BrdU detection,
slides were treated with 2 N HCl at 37 °C to denature DNA, and neu-
tralized in 0.1 M borate buffer pH 8.5. To quench endogenousperoxidases, slides were treated with 3% H2O2. Sections were
blocked in 3% BSA in Tris Buffered Saline Tween (TBST, 20 mM Tris
pH 7.4; 0.15 M NaCl; 0.1% Tween), endogenous biotin was blocked
using the Avidin–Biotin blocking kit (Vector Labs), and the sections
were incubated with a primary antibody at 4 °C in a humidiﬁed
chamber overnight (BrdU, 1:3, Roche; cleaved caspase 3, 1:500, Cell
Signaling Technology; Ki67, MIB1 clone, 1:200, Immunotech S.A.;
EMG1, 1:500, Protein Tech Group). Slides were incubatedwith biotinyl-
ated goat anti-rabbit secondary antibody (1:1000, Dako or Vector), and
the signal was ampliﬁed using the ABC complex and developed by the
Table 1
Genotype distributions from heterozygous intercrosses.
% observed
Age N A/A A/G G/G Resorptions
Weanlings observed total 71 33.8 66.2 0 N/A
Embryonic observed total 319 22.3 51.1 10.6 16.0
E 8.5 44 20.5 61.4 15.9 2.3
E 9.5 67 20.9 52.2 16.4 10.5
E 10.5 42 38.1 40.5 11.9 9.5
E 11.5 92 14.1 54.4 9.8 21.7
E 12.5 65 24.6 46.2 3.1 26.2
E 13.5 9 33.3 44.4 0 22.2
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sodium acetate pH 4.2) or hematoxylin was used to counterstain
the nuclei.Fig. 3. Neural tube defects in BCS embryos. Sections were stained with hematoxylin and
eosin. A–D showE11.5 embryoswith ventral to the top. (A, B) Transverse sections through
the top of the head showed an open neural tube in the BCS embryo (arrows), while the
neural tube had already closed in the control mouse. Original magniﬁcation 5×, scale
bar=500 μm. (C,D) In the same embryos,more caudal sections (at the level of the second
pharyngeal arch) showed an abnormal cross-shaped neural tube in the BCS embryo
(arrow), compared to the straight neural tube in the control. Original magniﬁcation
20×, scale bar = 100 μm. (E, F) Coronal sections of the head region of E12.5 embryos,
showing exencephaly in the BCS embryo (arrow). Original magniﬁcation 5×, scale
bar = 200 μm. (G, H) Dorsal dissecting microscope photographs of E12.5 embryos,
showing the closed, yet wavy, neural tube in the BCS embryo (dotted line). Note that
the control in (H) is Emg1A/A.2.5. Analysis of human tissue
Archival autopsy tissue from four Hutterite children with a clinical
diagnosis of BCS was reviewed. Among these were: 1) Female (sibling
to Patient 2 in [17]), stillborn at estimated 37 weeks gestation. Abnor-
malities at autopsy were low birth weight (2000 g), microcephaly,
micrognathia, and joint deformities. The tissues were severely autolytic
and could not be evaluated in detail. 2) Male born at ~35 weeks
gestation, survived 16 days (Patient 1 in [17]). Abnormalities at autopsy
were low body weight (1930 g), microcephaly (brain 247 g),
micrognathia, corneal opacities, rocker-bottom feet, joint contractures,
and hypoplastic nails. Microscopic abnormalities included multiple
small cysts in the kidneys, lymphocyte depletion in the thymus, and
small calciﬁcations in the cerebral white matter. 3) Male born at
~37 weeks gestation, survived 5 days. Abnormalities at autopsy were
low weight (2390 g), microcephaly (brain 213 g), micrognathia, prom-
inent nose, and ventricular septal defect in the heart. Microscopic ab-
normalities included bronchopneumonia, an ectopic collection of
immature cells on anterior surface of the pons, and many pyknotic
cells in the external granular layer of the cerebellum. 4) Female born
at term, survived 10 weeks after developing seizures and persistent
poor feeding. Abnormalities at autopsy were low weight (2700 g), mi-
crocephaly (brain 270 g), limb contractures, equinus deformity of feet,
abnormal ﬁnger position, right lung with four lobes, and gastrostomy.
In all cases bonemarrow appeared to be of normal cellularity on hema-
toxylin and eosin stained sections.
For analysis of EMG1 localization in normal human brain, archival
formalin-ﬁxed, parafﬁn-embedded sections from normal human brains
collected from neurologically normal 15 week fetus, full-term newborn,
and 55 year old adult were provided by the Department of Pathology at
the University of Manitoba in Winnipeg, Manitoba.
2.6. Isolation of MEFs
MEFs were isolated according to an adapted method [18]. Embryos
from timed heterozygous matings were collected at E11.5 in sterile
PBS, eviscerated, and the head removed. Embryos were minced, trans-
ferred into 0.05% trypsin/EDTA, 100 U DNase, and incubated at 37 °C
with pipetting to dissociate cells. Cells were washed with MEF medium
and plated.
2.7. Immunoﬂuorescence
MEFs and human ﬁbroblasts were grown to sub-conﬂuency on ster-
ilized glass coverslips, while human lymphoblastswere spunonto slides
(Shandon Cytospin). Cells were ﬁxed in 4% paraformaldehyde for
15 min, quenched using 50 mM ammonium chloride in PBS, and the
cell membrane was permeabilized with 0.1% Triton X-100 in PBS. Fol-
lowing blocking (3% bovine serum albumen, 0.05% Tween in PBS),
cells were incubated with primary antibody (α-tubulin Sigma-Aldrich
mouse monoclonal, 1:100; EMG1 Proteintech Group rabbit polyclonal,
1:500), washed, and incubated with Alexa Fluor 488- or 555-
conjugated secondary antibody (Molecular Probes, 1:1000). The nuclei
were stained using Hoechst 33258 (Invitrogen), and the cells were
mounted with Prolong Gold Antifade Reagent (Molecular Probes).
2.8. Immunoblot
To isolate the nuclear fraction from MEFs, cells were lysed in Triton
buffer (50 mM Tris pH 7.4; 1 mM EDTA; 150 mM NaCl; 1% Triton) and
the fractions were separated by centrifugation at 2000 ×g for 10 min.
The supernatant was removed and the pellet was resuspended by son-
ication in nuclear lysis buffer (50 mM Tris pH 7.4; 10 mM EDTA; 1%
SDS). Lysis buffers were supplemented 1 in 500 with a protease inhibi-
tor cocktail (Sigma). Equal protein concentrations (25 μg)were separat-
ed by SDS-PAGE in a 10% gel, and transferred to a nitrocellulose
Fig. 4. Cell proliferation and apoptosis. (A–D) Proliferating cells in BCS and control E9.5 littermates were detected by injecting pregnant females with BrdU. Embryo mid-sagittal sections
were stained using an anti-BrdU antibody. Compare the strong staining of the BCS embryo in (A) with the weaker staining of its BCS littermate in (C), particularly in the neuroepithelium
(arrows), and the underlying cranial mesenchyme (arrowheads). In comparison, all control littermates (B, D) were strongly stained. (E–H) Apoptotic cells were labeled using an anti-ac-
tivated caspase 3 antibody in E8.5 (E, F) and E9.5 littermates (G, H). Arrows indicate areas of strong staining. Note more generalized staining in BCS embryos. Scale bars at 5×= 200 μm,
20× = 50 μm.
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(CAPS) buffer (0.01 M CAPS pH 11, 10% methanol) at 100 V for 1 h at
4 °C. The membrane was blocked in 5% skim milk in TBST for 1 h.
EMG1 (Protein Tech Group rabbit polyclonal, 1:200) and actin (mouse
monoclonal Sigma, 1:5000) were detected by incubation with primary
antibodies overnight at 4 °C. Blots were washed three times with
TBST, incubated with horseradish peroxidase (HRP)-conjugated sec-
ondary donkey anti-rabbit or donkey anti-mouse antibody at a dilution
of 1:20,000 for 1 h, washed, and visualized using Immobilon western
chemiluminescent HRP substrate (Millipore).
2.9. Human and animal studies
This studywas approved by the Pathology Access Committee for Tis-
sue, and the University of Manitoba Biomedical Research Ethics Board.
In addition, all animal experiments were performed under protocols
approved by the University of Manitoba Animal Care Committee and
following the guidelines of the Canadian Council of Animal Care.3. Results
3.1. Generation of D86G EMG1 mice
EMG1 is strongly expressed in the neuroepithelium of mouse em-
bryos, and remains broadly expressed in the developing brain until
after birth, when expression becomes much more restricted (Fig. 1).
To study the progression of BCS during development and particularly
in the brain, we produced a knock-in mouse harboring the BCS-
causing D86G substitution in the EMG1 protein. A targeting construct
was generated containing exons 2–6 of Emg1with a single A to Gmuta-
tion in exon 2 that would introduce the D86G substitution (Fig. S1A).
Two independent correctly targeted ES cell clones were selected for gen-
eration of chimeras (Figs. S1B and S2A–Dx). Following removal of the SA-
IRES-βgeo selection cassette (Fig. S2E–F), heterozygotes (Emg1A/G) were
intercrossed to produce homozygous Emg1G/G or “BCS”mice. Genotyping
of progeny revealed 33.8%wild type and66.2%heterozygousmice, andno
homozygousmutants (χ2=23.68, p b 0.0001, Table 1, “weanlings” row).
Fig. 5. Cell proliferation in human bone marrow and brain. Cell proliferation was assessed
by immunolabeling of human autopsy tissues from control and age-matched BCS affected
infants. Ki67 positive cells (brown) are shown with hematoxylin counterstain (blue). (A,
B) At 35 weeks gestation (adjusted age) a large proportion of cells are cycling in normal
bone marrow, but only a few in the BCS case. (C, D) At the same time, there is a slight re-
duction in cellularity in the subventricular zone (SVZ) of the brain over the caudate nucle-
us, but only a modest reduction in the proportion of Ki67 positive cells. (E, F) At 2 months
post natal age, proliferation in the external granular layer (EGL) of the cerebellum is nor-
mally abundant, but in the BCS case there is a paucity of labeled cells. Bar = 100 μm.
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were genotyped.
3.2. Homozygous mutants die between E8.5 and E12.5
To establish the embryonic stage of lethality, timed Emg1A/G
intercrosses were performed, and embryos collected at E8.5 to E13.5
were genotyped using DNA isolated from the yolk sac or from
formaldehyde-ﬁxed, parafﬁn embedded tissue sections. The results are
summarized in Table 1. Contrary to the pre-implantation death inFig. 6. Binucleate BCS MEFs and perichromosomal EMG1 localization. (A–F) To visualize
the cytoskeleton in MEF cells, tubulin was detected using an anti α-tubulin antibody
(red), and nuclei were labeled with Hoechst 33258 (blue). (G) Cell counts from multiple
independent experiments revealed 28% of BCS MEF cells contained two nuclei (n = 226
cells). “Other” includes cells in mitosis and those with more than two nuclei. (H–M)
EMG1 (green) localizes to the nucleolus during interphase (arrowhead in L), and to the
perichromosomal layer during mitosis in BCS patient and control lymphoblasts (insets).
Original magniﬁcation 63×, scale bar = 20 μm.Emg1 null mice [8], Emg1G/G embryos were found between E8.5 and
E12.5, indicating that the level of residual protein function provided
by the mutant EMG1 protein was adequate to rescue growth beyond
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mutants, signiﬁcantly below the expected Mendelian proportion
of 25% (χ2 = 22.8, p b 0.0001) (Table 1, “Embryonic total” row). The
16.0% of resorption sites, where an implanted embryo later died, ac-
count for the missing homozygous mutants. The number of recovered
homozygous mutants decreased with embryonic age, accompanied by
an increase in resorption sites. Taken together, these results indicate
lethality is variable, and occurs between E8.5 and E12.5.
In BCS patient lymphoblasts and ﬁbroblasts, the level of EMG1 pro-
tein is reduced compared to control cells due to protein instability,
although the EMG1mRNA levels are unaffected [2,5]. We therefore ex-
pected a similar reduction in EMG1 protein in the BCS mouse model.
EMG1was detected by immunoblot in control and BCSMEF nuclear iso-
lates, revealing dramatically reduced levels in BCS mice compared to
controls (Fig. S1C). This suggests that the A to G mutation in Emg1 has
a similar destabilizing effect on the EMG1 protein in BCS patients and
in Emg1G/G mice. However, the dramatic reduction in the EMG1 level
in MEFs may indicate that the effect is more severe in mice than in
human BCS patients, as residual protein was readily detected in previ-
ous studies of BCS patient lymphoblasts or ﬁbroblasts [2,4,5]. As expect-
ed, residual levels of mutant EMG1 were detectable in mice, consistent
with a rescue from the preimplantation lethality which results when
EMG1 is completely absent [8].
3.3. Homozygous mutant embryos exhibit severe growth retardation and
neural tube defects
Emg1G/G embryos were easily differentiated fromwild type and het-
erozygous littermates by their severely reduced size, consistent with a
developmental delay of approximately one day. BCS embryos otherwise
appeared normalmorphologically, except for open neural tubes in some
BCS embryos (see below, and Fig. 2; controls are Emg1A/G littermates ex-
cept where indicated otherwise). A beating heart was observed in BCS
embryos fromE9.5 to E12.5, suggesting that theywere viable. Embryon-
ic death during this period often indicates defects in the initiation or
maintenance of blood circulation in the yolk sac, in chorioallantoic fu-
sion, or in placental formation [19]. Indeed, ribosome biogenesis disor-
ders are frequently associated with hematopoietic defects [20]. The
allantois fused normally with the chorion in BCS embryos at E9.5
(Fig. S3A, arrow), blood islands were visible in the yolk sac (asterisks
in Fig. S3A, B), and placentas of BCS embryos appeared grossly normal
(Fig. S3C). The pericardial swelling associated with placental defects
was not observed. However, placental labyrinths from BCS embryos at
E11.5 and E12.5 were less extensive than controls, with fewer fetal
red blood cells (Fig. S3D–G). Thus placental insufﬁciency may further
exacerbate developmental delay in BCS embryos.
Proper cranial neural tube closure in the mouse begins at about E8.5
in the hindbrain, and terminates by E9.5 [21]. Approximately 50% of BCS
embryos, which exhibited morphology otherwise consistent with a
stage beyond neural tube closure, had an open cranial neural tube
(E10.5 to E12.5, Fig. 3 and Fig. S4). Eversion of the neural folds led to
exencephaly by E12.5 (Fig. 2J, arrowhead, and Fig. 3E, arrow). The spinal
neural tube, by contrast, was closed in all BCS embryos. However, trans-
verse sections at the level of the second pharyngeal arch in E10.5 to
E12.5 BCS embryos with an open neural tube revealed an abnormal
cross-shape (Fig. 3C–D and Fig. S4). Of the two BCS embryos recovered
at E12.5, one had exencephaly (Fig. 3E, arrow) and collapsed telence-
phalic vesicles (arrowhead), and the other had a wavy neural tube, de-
spite complete closure (Fig. 3G, dotted line).
3.4. Cell proliferation is reduced and apoptosis is increased in homozygous
mutant embryos
To assess cell proliferation rates in mouse embryos, pregnant fe-
maleswere injectedwith BrdU. Time points from E7.5 to E9.5were cho-
sen because they reliably yielded viable Emg1G/G embryos (n = 3pregnant females per timepoint). Control embryos consistently showed
strong BrdU staining in themajority of cells (Fig. 4B and D). By contrast,
staining in BCS embryos was much more variable. Some displayed
strong staining similar to that of controls (n = 3/8 BCS embryos)
(Fig. 4A vs B), but others had reduced or nearly absent BrdU levels
(n = 5/8) (Fig. 4C vs D). Even within the same litter, BCS embryos
were observed with differing levels of staining (compare Fig. 4A and C).
The reduction in cell proliferation rates in the BCS embryos may be
accompanied by increased cell death. In control embryos, the apoptosis
marker cleaved caspase 3 was concentrated in areas where apoptosis is
expected during development (Fig. 4F and H). However, activated cas-
pase 3 immunostaining in BCS embryos was frequently more wide-
spread and not conﬁned to areas where apoptosis is known to occur
in healthy embryos (Fig. 4E and G). Taken together, these data indicate
that the D86G substitution in EMG1 causes a reduction of cell prolifera-
tion and increased cell death during development, the severity of which
likely affects the developmental stage to which an embryo can survive.3.5. Cell proliferation is severely reduced in BCS patient tissues, including
the brain
EMG1 is expressed in the human brain throughout development and
in adulthood (Fig. S5). To test the hypothesis that BCS is associated with
reduced cell proliferation, autopsy tissue samples from two BCS patients
(cases 2 and 4, see Materials and methods) along with age-matched
controls were examined. Sections of rib bone marrow, caudate nucleus
head and cerebellum were immunostained with Ki67, which is
expressed by proliferating cells [22] and at sites of ribosomal RNA tran-
scription [23]. In all locations the proportion of cells expressing Ki67
was dramatically less in the BCS cases (Fig. 5), indicating a generalized
deﬁcit in cell proliferation. Further examination of brain tissue from
two BCS patients revealed collections of immature cells on the anterior
aspect of the pons; foci of these extended heterotopically into the
leptomeninges (Supplemental Fig. 6). Cell clusters such as these are
very unusual in this prepontine location, and suggest a possible migra-
tion abnormality.3.6. Perichromosomal localization of EMG1 duringmitosis underlies a binu-
cleate phenotype in BCS cells
To examine the causes underlying the BCS proliferation defect, MEF
cells were isolated at E11.5. Surprisingly, approximately 30% of cultured
BCS MEF cells contained two nuclei, while control lines appeared
normal (Fig. 6A–G), indicating a possible defect during mitosis. This is
consistent with the G2/M delay which we previously observed in BCS
patient lymphoblasts, as well as numerous reports of mitotic or
cytokinetic defects in cells deﬁcient in other ribosomebiogenesis factors
[24–27], reviewed in [28]. Many ribosomal biogenesis factors and pre-
rRNA move from the nucleolus to the mitotic spindle or the
perichromosomal layer duringmitosis [29–36]. Furthermore,mutations
in perichromosomal proteins have been shown to lead to increased
binucleation following mitotic defects [37]. As expected for a ribosome
biogenesis factor, EMG1 is present in the nucleolus during interphase
[5] (Fig. 6L, arrowhead), yet its yeast homologue localizes to an area
consistentwith themetaphase spindle duringmitosis [7].We examined
EMG1 in mitotic human lymphoblasts and ﬁbroblasts, and found that it
localizes to the periphery of chromosomes, in contrast to its interphase
nucleolar localization (Fig. 6H–M and Fig. S7). Taken together, these
results strongly suggest that EMG1 may play an important extra-
ribosomal role duringmitosis, though further investigation is necessary
to determine if this is a direct effect.We hypothesize that a reduction in
EMG1 levels leads to mitotic defects, accounting for the reduced prolif-
eration in BCS patient cell lines [4] and tissues including the brain, as
well as in our BCS mouse model.
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We generated mice homozygous for the EMG1 D86G substitution in
order to study the etiology of BCS throughout embryonic development.
BCS mice died prenatally, between E8.5 and E12.5, accompanied by se-
vere intrauterine growth retardation and failure of neural tube closure.
Death was apparently caused by reduced cell proliferation concomitant
with increased apoptosis, most likely due to a defect in mitosis. This
mouse model of BCS recapitulates the severe developmental delay
seen in human BCS patients, which we showed is also accompanied
by severely reduced cell proliferation. We conﬁrmed that the mutation
in Emg1 disrupts development of the central nervous system, and
established that mitotic defects underlie the BCS phenotype. These re-
sults may shed light on the only other ribosomopathy to be associated
primarily with abnormalities in brain development, an X-linked deﬁ-
ciency of the large ribosomal subunit protein Rpl10 [38].
The link between mitotic arrest and ribosome biogenesis is a recur-
ring theme in the ribosomopathies. We previously described G2/M ac-
cumulation and slow proliferation rates in BCS patient lymphoblasts
[4]. However, accumulation at G2/M and/or mitotic spindle defects
have also been observed in other ribosomebiogenesis disorders, includ-
ing Shwachman–Diamond syndrome [35], Treacher Collins syndrome
[34], X-linked dyskeratosis congenita [33,39], and North American
Indian childhood cirrhosis [36]. The factors responsible for these disor-
ders frequently re-localize to the mitotic spindle or the chromosome
periphery during mitosis, similar to EMG1 (Fig. 6H–M). Given the
perichromosomal localization of EMG1 during mitosis and the binucle-
ate phenotype in BCS MEFs (Fig. 6), the cell proliferation delay could be
the result of mitotic slippage following spindle assembly checkpoint ar-
rest [40,41]. Although none of the autopsy samples displayed abnormal-
ly multinucleate cells, this could indicate that cells cannot undergo
mitotic slippage in vivo, and instead remain arrested at the spindle as-
sembly checkpoint. It is unclear whether this mitotic arrest is speciﬁc
to EMG1 deﬁciency, or a common response to defects in the ribosome
biogenesis pathway. This important link between ribosome biogenesis
factors and maintenance of the mitotic spindle could contribute to the
increased cancer incidence in ribosomopathies [42], yet is currently
under-appreciated and poorly understood.
All BCS embryos were developmentally delayed by approximately
one day, and many had defects in the formation of the neural tube,
the precursor to the central nervous system (Fig. 3). EMG1 is most
strongly expressed in rapidly proliferating cells and tissues (Fig. 1 and
our unpublished data), which may therefore be more susceptible to
mitotic arrest caused by a severe reduction in EMG1 levels. The
neuroepithelium is very highly proliferative, and neuroepithelial cells
exit the cell cycle and begin to differentiate only after the neural tube
has closed [21]. The reduced BrdU labeling in BCS embryos in the
neuroepithelium (Fig. 4C, arrow) and the subjacent mesenchyme (ar-
rowhead), suggest that proliferation is insufﬁcient to elevate and close
the neural folds [43]. The importance of methylation and the folate/
one-carbon cycle in proper neural tube closure is well-established
[44], and suggests that a disruption of the EMG1 methyltransferase
functionmay be responsible for the open neural tube in BCSmouse em-
bryos. Neural tube defects in animal models are frequently attributed to
critical methylation of proteins [45] or DNA [46]. Given the rRNAmeth-
yltransferase activity of EMG1 [3], it seems plausible to speculate that
the neural tube defects in BCS embryos are a result of deﬁciencies of
rRNA methylation, rather than of proteins or of DNA. Studies in
zebraﬁsh indicate that loss of rRNA methylation at a single site can dis-
rupt brain development [47].
The variable phenotype exhibited by the BCS embryos is common in
the ribosomopathies [48–50], and is not unexpected on a mixed CD1/
C129/C57BL/6 background. We are currently establishing a congenic
C57BL/6 line to address genetic background effects on phenotypic vari-
ability. Nevertheless, it raises the possibility that the BCS phenotype in
humans may be broader than currently understood, and that othermutations in EMG1 may exist, but are currently unrecognized due to
prenatal lethality. In addition, the establishment of a mouse model of
BCS will now allow testing of treatments for this disease. One potential
treatment is S-adenosyl methionine (SAM), the methyl donor in the
methyltransferase reaction performed by EMG1. Excess exogenous
SAM or SAM synthase rescues an Emg1 mutant in yeast, likely by stabi-
lization of the protein upon SAM binding [7]. Since EMG1 is transcribed
at normal levels in BCS patient cells [2], stabilization of D86G EMG1 by
SAMcould restore normal levels of theprotein. SAM is already approved
for use as an anti-depressant in humans [51,52], meaning that it would
be readily available to families if it showed promise in mouse studies.
While BCS is currently the ribosomopathy with the most severe
neurological defects, several others display neurological defects
to varying degrees, including Treacher Collins syndrome [53],
anauxetic dysplasia [54], alopecia, neurological defects and
endocrinopathy syndrome [55], and a recently described novel X-
linked intellectual disability [38]. A link between ribosome biogen-
esis, mitotic progression, and neurogenesis was shown in a mouse
model of Treacher Collins syndrome [34], but has never been explored
in the context of other ribosomopathies. Our results suggest thatmitotic
defects, brought on by ribosome biogenesis dysfunction, may disrupt
brain development in a manner much more common than previously
thought.
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